People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Healthtech, Other, Biotechnology, Pharmaceuticals, Proptech / Real Estate
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| T2 Biosystems, Inc. | — | Other Technology | Series D+ | $477.6M | $1.3B | 2010 |
| Cohere Health Inc. | — | Healthtech | Series C | $166.1M | $604.1M | 2021 |
| HealthVerity, Inc. | — | Healthtech | Series D+ | $146.2M | $2.1B | 2016 |
| higi SH Holdings Inc. | — | Other | Series B | $55.2M | $521.9M | 2020 |
| Taris Biomedical Inc | — | Biotechnology | Series B | $36.9M | $535.8M | 2009 |
| SpringLeaf Therapeutics, Inc. | — | Pharmaceuticals | Series B | $34.1M | $647.7M | 2011 |
| Home Hospital Newco, Inc. | — | Proptech / Real Estate | Series B | $32.2M | $171.8M | 2022 |
| MicroCHIPS, Inc. | — | Biotechnology | Series B | $27.9M | $740.1M | 2009 |
| Predictive Biosciences, Inc | — | Biotechnology | Series B | $26.8M | $1.0B | 2010 |
| Predilytics, Inc. | — | Other Technology | Series A | $19.5M | $247.2M | 2012 |
| OnCall Health Corp | — | Healthtech | Series A | $18.7M | $24.9M | 2021 |
| PolyRemedy Inc | — | Other Health Care | Series A | $13.7M | $10.9M | 2009 |
| Aspen Health, Inc. | — | Healthtech | Series A | $6.0M | $135.4M | 2018 |
| RightMove Holdings Inc. | — | Hospitals and Physicians | Series A | $4.5M | $41.5M | 2022 |
| Lighter Living, Inc. | — | Retailing | Seed | $3.0M | $19.2M | 2009 |
Michael Greeley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Greeley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 4 | 36 |
| Michael Cima | 3 | 4 |
| Robert S Langer | 2 | 14 |
| Robert Crane | 2 | 7 |
| Ian Chiang | 2 | 5 |
| Ian Sigalow | 1 | 16 |
| Garheng Kong | 1 | 16 |
| Kevin Bitterman | 1 | 15 |
| Andrew Firlik | 1 | 14 |
| David Barrett | 1 | 13 |
| Glen Tullman | 1 | 12 |
| Annette Campbell-White | 1 | 11 |
| Brian Gallagher | 1 | 11 |
| Anna Haghgooie | 1 | 11 |
| Alan Crane | 1 | 9 |
| John Collins | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Patrick Flynn | 1 | 8 |
| Robert Higgins | 1 | 7 |
| Jeffrey McCarthy | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.